The findings have already prompted recalls in more than 50 countries, affecting several Chinese and Indian companies.  (iStock) European and North American regulators have said they are examining a second potentially cancer-causing substance in a commonly-used blood pressure drug made by Chinese firm Zhejiang Huahai Pharmaceuticals. Statements from health regulators in the EU, United States